Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with Zeto, a leading EEG brain monitoring technology innovator. The collaboration will integrate Firefly's proprietary Brain Network Analytics (BNA™) technology with Zeto's FDA-cleared EEG platform, currently used in over 200 hospitals and neurology offices nationwide. Firefly will act as a non-exclusive distributor of Zeto's EEG headset devices, cloud platform, and services, expanding its accessibility to healthcare providers.
This partnership aims to offer deeper insights into neurological conditions, potentially improving patient outcomes. Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE) are designed for various clinical settings, including ICUs, EDs, hospitals, offices, and homes. The integration with Firefly's BNA™ platform is expected to enable more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
Firefly Neuroscience (NASDAQ: AIFF) ha annunciato una partnership strategica con Zeto, un'azienda leader nell'innovazione della tecnologia di monitoraggio EEG. La collaborazione integrerà la tecnologia esclusiva di Firefly, Brain Network Analytics (BNA™), con la piattaforma EEG approvata dalla FDA di Zeto, attualmente utilizzata in oltre 200 ospedali e studi neurologici a livello nazionale. Firefly agirà come distributore non esclusivo dei dispositivi headset EEG di Zeto, della piattaforma cloud e dei servizi, ampliando la loro accessibilità per i fornitori di assistenza sanitaria.
Questa partnership mira a offrire approfondimenti più dettagliati sulle condizioni neurologiche, con potenziali miglioramenti nei risultati per i pazienti. Gli headset EEG approvati dalla FDA di Zeto (WR19 e Zeto ONE) sono progettati per diversi contesti clinici, tra cui le UCIs, i pronto soccorsi, gli ospedali, gli uffici e le abitazioni. L'integrazione con la piattaforma BNA™ di Firefly si prevede permetterà un'analisi più precisa e un uso ampliato della tecnologia EEG, ottimizzando la diagnosi per una vasta gamma di disturbi neurologici.
Firefly Neuroscience (NASDAQ: AIFF) ha anunciado una asociación estratégica con Zeto, un innovador líder en tecnología de monitoreo cerebral EEG. La colaboración integrará la tecnología propietaria de Firefly, Brain Network Analytics (BNA™), con la plataforma EEG aprobada por la FDA de Zeto, que se utiliza actualmente en más de 200 hospitales y consultorios de neurología a nivel nacional. Firefly actuará como distribuidor no exclusivo de los dispositivos auriculares EEG de Zeto, su plataforma en la nube y servicios, ampliando su accesibilidad para los proveedores de atención médica.
Este acuerdo tiene como objetivo ofrecer una visión más profunda de las condiciones neurológicas, lo que podría mejorar los resultados para los pacientes. Los auriculares EEG aprobados por la FDA de Zeto (WR19 y Zeto ONE) están diseñados para diversos entornos clínicos, incluyendo UCI, salas de emergencias, hospitales, consultorios y hogares. Se espera que la integración con la plataforma BNA™ de Firefly permita un análisis más preciso y un uso ampliado de la tecnología EEG, optimizando los diagnósticos para una amplia gama de trastornos neurológicos.
파이어플라이 신경과학(Firefly Neuroscience)(NASDAQ: AIFF)이 EEG 뇌 모니터링 기술의 선두주자인 제토(Zeto)와 전략적 파트너십을 발표했습니다. 이번 협력은 파이어플라이의 독점 기술인 Brain Network Analytics (BNA™)와 제토의 FDA 승인을 받은 EEG 플랫폼을 통합할 예정이며, 현재 200개 이상의 병원 및 신경과 사무실에서 사용되고 있습니다. 파이어플라이는 제토의 EEG 헤드셋 장치, 클라우드 플랫폼 및 서비스를 비독점적으로 유통하며, 의료 제공자에 대한 접근성을 확장합니다.
이번 파트너십은 신경학적 조건에 대한 깊은 통찰력을 제공하여 환자 결과를 개선하는 것을 목표로 합니다. 제토의 FDA 승인을 받은 EEG 헤드셋(WR19 및 Zeto ONE)은 ICU, ED, 병원, 진료소 및 가정 등 다양한 임상 환경을 위해 설계되었습니다. Firefly의 BNA™ 플랫폼과의 통합은 EEG 기술의 보다 정밀한 분석과 활용을 가능하게 하여, 다양한 신경장애 진단의 최적화를 기대하고 있습니다.
Firefly Neuroscience (NASDAQ: AIFF) a annoncé un partenariat stratégique avec Zeto, un leader de l'innovation en technologie de surveillance cérébrale EEG. La collaboration intégrera la technologie exclusive de Firefly, Brain Network Analytics (BNA™), avec la plateforme EEG approuvée par la FDA de Zeto, actuellement utilisée dans plus de 200 hôpitaux et cabinets de neurologie à travers le pays. Firefly agira en tant que distributeur non exclusif des dispositifs de casque EEG de Zeto, de sa plateforme cloud et de ses services, augmentant ainsi leur accessibilité pour les fournisseurs de soins de santé.
Ce partenariat vise à offrir des connaissances plus approfondies sur les affections neurologiques, ce qui pourrait améliorer les résultats pour les patients. Les casques EEG approuvés par la FDA de Zeto (WR19 et Zeto ONE) sont conçus pour divers environnements cliniques, y compris les soins intensifs, les urgences, les hôpitaux, les cabinets et les domiciles. L'intégration avec la plateforme BNA™ de Firefly devrait permettre une analyse plus précise et une utilisation élargie de la technologie EEG, optimisant ainsi le diagnostic d'un large éventail de troubles neurologiques.
Firefly Neuroscience (NASDAQ: AIFF) hat eine strategische Partnerschaft mit Zeto, einem führenden Innovator im Bereich der EEG-Gehirnüberwachungstechnologie, bekannt gegeben. Die Zusammenarbeit wird die proprietäre Technologie von Firefly, Brain Network Analytics (BNA™), mit der von der FDA zugelassenen EEG-Plattform von Zeto integrieren, die derzeit in über 200 Krankenhäusern und neurologischen Praxen im ganzen Land verwendet wird. Firefly wird als nicht-exklusiver Distributor für die EEG-Headset-Geräte, die Cloud-Plattform und die Dienstleistungen von Zeto fungieren, um die Zugänglichkeit für Gesundheitsdienstleister zu erweitern.
Diese Partnerschaft zielt darauf ab, tiefere Einblicke in neurologische Erkrankungen zu bieten, was potenziell zu besseren Patientenergebnissen führen könnte. Die von der FDA zugelassenen EEG-Headsets von Zeto (WR19 und Zeto ONE) sind für verschiedene klinische Umgebungen konzipiert, darunter Intensivstationen, Notaufnahmen, Krankenhäuser, Praxen und Wohnungen. Die Integration mit der BNA™-Plattform von Firefly wird voraussichtlich eine genauere Analyse und eine erweiterte Nutzung der EEG-Technologie ermöglichen und die Diagnostik für eine Vielzahl neurologischer Störungen optimieren.
- Strategic partnership with Zeto expands Firefly's market reach to over 200 hospitals and neurology offices
- Integration of Firefly's BNA™ technology with Zeto's FDA-cleared EEG platform may enhance diagnostic capabilities
- Non-exclusive distribution agreement for Zeto's products potentially increases Firefly's revenue streams
- Collaboration aims to improve patient outcomes in neurological and mental disorders
- Non-exclusive nature of the distribution agreement may limit Firefly's competitive advantage
- Success of the partnership depends on effective integration of technologies and market adoption
This partnership between Firefly Neuroscience and Zeto marks a significant advancement in neurological diagnostics. By integrating Firefly's BNA™ technology with Zeto's FDA-cleared EEG devices, healthcare providers will gain access to more comprehensive brain health insights. The collaboration addresses a important unmet medical need, potentially improving diagnosis and treatment for various neurological disorders.
The synergy between Zeto's user-friendly EEG hardware and Firefly's advanced analytics could lead to more accurate and timely diagnoses. This is particularly valuable in settings like ICUs and EDs, where rapid assessment is critical. The cloud-based platform and AI-powered seizure detection further enhance the system's utility, potentially reducing the workload on neurologists and improving patient care efficiency.
This strategic partnership has positive implications for both companies. For Firefly, it expands their market reach by leveraging Zeto's existing presence in over 200 hospitals and neurology offices. This could significantly accelerate Firefly's revenue growth and market penetration. For Zeto, integrating Firefly's BNA™ technology adds value to their existing product line, potentially increasing their competitive edge in the medical device market.
The non-exclusive nature of the distribution agreement allows both companies to maintain flexibility while benefiting from each other's strengths. This collaboration could lead to increased adoption of advanced neurological diagnostic tools, potentially expanding the overall market size. Investors should monitor how this partnership translates into revenue growth and market share gains for both companies in the coming quarters.
This partnership exemplifies the growing trend of AI integration in healthcare diagnostics. By combining Firefly's AI-driven BNA™ technology with Zeto's hardware, the collaboration is pushing the boundaries of what's possible in neurological assessments. The ease of use of Zeto's devices, coupled with the analytical power of Firefly's platform, could democratize access to advanced brain health diagnostics.
The potential for at-home monitoring is particularly noteworthy, as it aligns with the broader shift towards telemedicine and remote patient care. This could lead to more continuous monitoring of neurological conditions, potentially improving treatment outcomes and patient quality of life. However, the success of this venture will depend on factors such as reimbursement policies, clinician adoption rates and the ability to demonstrate clear clinical benefits over existing diagnostic methods.
Partnership will expand Firefly’s FDA Cleared BNA™ technology to more hospitals and physician offices
TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a strategic partnership with Zeto, Inc. (“Zeto”), a leading innovator in EEG brain monitoring technology. Under the agreement, Firefly will act as a non-exclusive distributor of Zeto’s FDA-cleared EEG headset devices, cloud platform and services, expanding Firefly’s accessibility to healthcare providers and institutions. This collaboration will also integrate Firefly’s proprietary Brain Network Analytics (BNA™) technology with Zeto’s advanced EEG platform, which is currently being used in more than 200 hospitals and neurology offices across the country.
"This collaboration of two progressive technology companies represents a major step forward in addressing an unmet medical need in brain health," said Jon Olsen, CEO of Firefly. "By combining Zeto’s innovative hardware with our proprietary BNA™ technology, this partnership will offer healthcare providers deeper insights into neurological conditions that will ultimately improve patient outcomes.”
Zeto’s EEG headsets - WR19 and Zeto ONE - are FDA-cleared, full-montage, and easy to use, making brain monitoring accessible across various clinical settings, including the ICU, ED, hospital, office, and home. Supported by a robust cloud-based platform, Zeto offers nationwide monitoring and interpretation services by neurologists, along with AI-powered seizure detection and video capabilities. As part of the distribution agreement, Firefly will offer Zeto’s devices and cloud services to its customers, allowing healthcare professionals to access, analyze, and store EEG data in real-time. The integration with Firefly’s BNA™ platform enables more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
Zeto’s Founder and CEO, Aswin Gunasekar, stated, “We are excited to partner with Firefly to offer customers more valuable tools, helping expand our user base and improving the value of EEG. By integrating Firefly’s BNA™ offering with Zeto’s EEG platform, we are able to advance our mission of positively impacting patients' lives through transformative, user-friendly, and best-in-class solutions.”
For more information on this partnership and the services offered, please visit: https://fireflyneuro.com/.
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
About Zeto, Inc.
Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare. Offering wearable devices, Zeto makes brain monitoring accessible across various clinical settings including the ICU, ED, hospital, office, and home. Supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled detection for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury.
Forward-Looking Statements
Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
FAQ
What is the partnership between Firefly Neuroscience (AIFF) and Zeto?
How many hospitals and neurology offices currently use Zeto's EEG platform?
What are the potential benefits of the Firefly-Zeto partnership for healthcare providers?
Which Zeto EEG headsets will Firefly Neuroscience (AIFF) distribute?
